Continuity Or Change? Roche’s New CEO And Pharma Leader Take On Big Strategy Question
Severin Schwan Replaced After 15 Years
Roche will suffer a hangover from its COVID-19 successes this year as revenues stagnate and its future strategy is yet to be laid out by incoming CEO Thomas Schinecker.
You may also be interested in...
Ease The Pain – Making Payment Models, Tech, Integration Work For Patients
Multiple payment models, including differential pricing for pooled purchases, and technology-based healthcare platforms are some of the ways to build a patient-centric ecosystem said officials from Roche, VCs and non-government bodies at a recent conference
Phase III Success For Roche’s Crovalimab In Crowded PNH Market
Roche is looking to challenge AstraZeneca's dominance in PNH with its subcutaneously administered once-a-month treatment but could struggle to rival the company's and Novartis’s oral therapy.
Pharma Leader Bill Anderson Makes Rapid Exit From Roche
Bill Anderson is leaving Roche after leading its pharma division through the loss of three oncology blockbusters and the launch of a new generation of blood cancer therapies.